Vertex Pharmaceuticals Stock Forecast - Naive Prediction
| VRTX Stock | USD 468.41 1.06 0.23% |
The Naive Prediction forecasted value of Vertex Pharmaceuticals on the next trading day is expected to be 469.47 with a mean absolute deviation of 6.68 and the sum of the absolute errors of 414.46. Vertex Stock Forecast is based on your current time horizon.
At this time the rsi of Vertex Pharmaceuticals' share price is below 20 . This entails that the stock is significantly oversold. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards. Momentum 0
Sell Peaked
Oversold | Overbought |
Quarterly Earnings Growth 0.047 | EPS Estimate Next Quarter 4.8961 | EPS Estimate Current Year 18.4284 | EPS Estimate Next Year 20.2079 | Wall Street Target Price 504.04 |
Using Vertex Pharmaceuticals hype-based prediction, you can estimate the value of Vertex Pharmaceuticals from the perspective of Vertex Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Vertex Pharmaceuticals using Vertex Pharmaceuticals' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Vertex using crowd psychology based on the activity and movement of Vertex Pharmaceuticals' stock price.
Vertex Pharmaceuticals Short Interest
An investor who is long Vertex Pharmaceuticals may also wish to track short interest. As short interest increases, investors should be becoming more worried about Vertex Pharmaceuticals and may potentially protect profits, hedge Vertex Pharmaceuticals with its derivative instruments, or be ready for some potential downside.
200 Day MA 436.9353 | Short Percent 0.0224 | Short Ratio 3.84 | Shares Short Prior Month 4.3 M | 50 Day MA 445.8546 |
Vertex Pharmaceuticals Hype to Price Pattern
Investor biases related to Vertex Pharmaceuticals' public news can be used to forecast risks associated with an investment in Vertex. The trend in average sentiment can be used to explain how an investor holding Vertex can time the market purely based on public headlines and social activities around Vertex Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Vertex Pharmaceuticals Implied Volatility | 0.38 |
Vertex Pharmaceuticals' implied volatility exposes the market's sentiment of Vertex Pharmaceuticals stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Vertex Pharmaceuticals' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Vertex Pharmaceuticals stock will not fluctuate a lot when Vertex Pharmaceuticals' options are near their expiration.
The Naive Prediction forecasted value of Vertex Pharmaceuticals on the next trading day is expected to be 469.47 with a mean absolute deviation of 6.68 and the sum of the absolute errors of 414.46. Vertex Pharmaceuticals after-hype prediction price | USD 466.53 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of Vertex Pharmaceuticals to cross-verify your projections. Prediction based on Rule 16 of the current Vertex contract
Based on the Rule 16, the options market is currently suggesting that Vertex Pharmaceuticals will have an average daily up or down price movement of about 0.0238% per day over the life of the 2026-04-17 option contract. With Vertex Pharmaceuticals trading at USD 468.41, that is roughly USD 0.11 . If you think that the market is fully incorporating Vertex Pharmaceuticals' daily price movement you should consider acquiring Vertex Pharmaceuticals options at the current volatility level of 0.38%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Open Interest Against 2026-04-17 Vertex Option Contracts
Although open interest is a measure utilized in the options markets, it could be used to forecast Vertex Pharmaceuticals' spot prices because the number of available contracts in the market changes daily, and new contracts can be created or liquidated at will. Since open interest in Vertex Pharmaceuticals' options reflects these daily shifts, investors could use the patterns of these changes to develop long and short-term trading strategies for Vertex Pharmaceuticals stock based on available contracts left at the end of a trading day.
Please note that to derive more accurate forecasting about market movement from the current Vertex Pharmaceuticals' open interest, investors have to compare it to Vertex Pharmaceuticals' spot prices. As Ford's stock price increases, high open interest indicates that money is entering the market, and the market is strongly bullish. Conversely, if the price of Vertex Pharmaceuticals is decreasing and there is high open interest, that is a sign that the bearish trend will continue, and investors may react by taking short positions in Vertex. So, decreasing or low open interest during a bull market indicates that investors are becoming uncertain of the depth of the bullish trend, and a reversal in sentiment will likely follow.
Vertex Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine Vertex price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Vertex using various technical indicators. When you analyze Vertex charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Forecasting cash, or other financial indicators, requires analysts to apply different statistical methods, techniques, and algorithms to find hidden patterns within the Vertex Pharmaceuticals' financial statements to predict how it will affect future prices.
Cash | First Reported 1990-12-31 | Previous Quarter 5 B | Current Value 4.9 B | Quarterly Volatility 2.7 B |
Vertex Pharmaceuticals Naive Prediction Price Forecast For the 25th of January
Given 90 days horizon, the Naive Prediction forecasted value of Vertex Pharmaceuticals on the next trading day is expected to be 469.47 with a mean absolute deviation of 6.68, mean absolute percentage error of 72.30, and the sum of the absolute errors of 414.46.Please note that although there have been many attempts to predict Vertex Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Vertex Pharmaceuticals' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Vertex Pharmaceuticals Stock Forecast Pattern
| Backtest Vertex Pharmaceuticals | Vertex Pharmaceuticals Price Prediction | Buy or Sell Advice |
Vertex Pharmaceuticals Forecasted Value
In the context of forecasting Vertex Pharmaceuticals' Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Vertex Pharmaceuticals' downside and upside margins for the forecasting period are 467.70 and 471.24, respectively. We have considered Vertex Pharmaceuticals' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Vertex Pharmaceuticals stock data series using in forecasting. Note that when a statistical model is used to represent Vertex Pharmaceuticals stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 124.2292 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 6.6848 |
| MAPE | Mean absolute percentage error | 0.015 |
| SAE | Sum of the absolute errors | 414.4583 |
Predictive Modules for Vertex Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Vertex Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Vertex Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Vertex Pharmaceuticals After-Hype Price Prediction Density Analysis
As far as predicting the price of Vertex Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Vertex Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Vertex Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Vertex Pharmaceuticals Estimiated After-Hype Price Volatility
In the context of predicting Vertex Pharmaceuticals' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Vertex Pharmaceuticals' historical news coverage. Vertex Pharmaceuticals' after-hype downside and upside margins for the prediction period are 464.76 and 515.25, respectively. We have considered Vertex Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Vertex Pharmaceuticals is very steady at this time. Analysis and calculation of next after-hype price of Vertex Pharmaceuticals is based on 3 months time horizon.
Vertex Pharmaceuticals Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Vertex Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vertex Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Vertex Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.19 | 1.77 | 1.88 | 0.42 | 8 Events / Month | 7 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
468.41 | 466.53 | 0.40 |
|
Vertex Pharmaceuticals Hype Timeline
Vertex Pharmaceuticals is at this time traded for 468.41. The entity has historical hype elasticity of -1.88, and average elasticity to hype of competition of 0.42. Vertex is anticipated to decline in value after the next headline, with the price expected to drop to 466.53. The average volatility of media hype impact on the company price is about 17.93%. The price decrease on the next news is expected to be -0.4%, whereas the daily expected return is at this time at 0.19%. The volatility of related hype on Vertex Pharmaceuticals is about 79.34%, with the expected price after the next announcement by competition of 468.83. About 98.0% of the company outstanding shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.58. Vertex Pharmaceuticals recorded earning per share (EPS) of 14.21. The entity had not issued any dividends in recent years. The firm had 2:1 split on the 24th of August 2000. Given the investment horizon of 90 days the next anticipated press release will be in about 8 days. Check out Historical Fundamental Analysis of Vertex Pharmaceuticals to cross-verify your projections.Vertex Pharmaceuticals Related Hype Analysis
Having access to credible news sources related to Vertex Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict Vertex Pharmaceuticals' future price movements. Getting to know how Vertex Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Vertex Pharmaceuticals may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| MCK | McKesson | 11.37 | 9 per month | 1.24 | (0.01) | 2.19 | (2.22) | 5.78 | |
| HCA | HCA Holdings | 4.59 | 10 per month | 1.46 | 0.05 | 2.91 | (2.71) | 8.70 | |
| MDT | Medtronic PLC | (2.43) | 29 per month | 0.84 | 0.01 | 2.41 | (1.62) | 6.95 | |
| SNY | Sanofi ADR | (0.11) | 9 per month | 0.00 | (0.15) | 2.01 | (2.16) | 7.20 | |
| REGN | Regeneron Pharmaceuticals | (6.29) | 8 per month | 1.25 | 0.15 | 4.60 | (2.47) | 15.67 | |
| GSK | GlaxoSmithKline PLC ADR | (0.04) | 11 per month | 1.29 | 0.07 | 2.41 | (2.17) | 8.39 | |
| BMY | Bristol Myers Squibb | (1.20) | 7 per month | 1.01 | 0.16 | 3.59 | (1.98) | 11.16 | |
| ARGX | argenx NV ADR | 21.99 | 9 per month | 0.00 | (0.09) | 2.28 | (2.47) | 7.04 | |
| CVS | CVS Health Corp | (0.39) | 11 per month | 1.69 | (0.02) | 2.35 | (1.95) | 6.40 | |
| SYK | Stryker | (5.18) | 7 per month | 0.00 | (0.13) | 2.16 | (2.03) | 6.72 |
Other Forecasting Options for Vertex Pharmaceuticals
For every potential investor in Vertex, whether a beginner or expert, Vertex Pharmaceuticals' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Vertex Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Vertex. Basic forecasting techniques help filter out the noise by identifying Vertex Pharmaceuticals' price trends.Vertex Pharmaceuticals Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Vertex Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Vertex Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Vertex Pharmaceuticals by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Vertex Pharmaceuticals Market Strength Events
Market strength indicators help investors to evaluate how Vertex Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Vertex Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying Vertex Pharmaceuticals stock market strength indicators, traders can identify Vertex Pharmaceuticals entry and exit signals to maximize returns.
| Accumulation Distribution | 21491.24 | |||
| Daily Balance Of Power | 0.1395 | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 466.54 | |||
| Day Typical Price | 467.16 | |||
| Price Action Indicator | 2.4 | |||
| Period Momentum Indicator | 1.06 |
Vertex Pharmaceuticals Risk Indicators
The analysis of Vertex Pharmaceuticals' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Vertex Pharmaceuticals' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting vertex stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 1.22 | |||
| Semi Deviation | 1.2 | |||
| Standard Deviation | 1.72 | |||
| Variance | 2.96 | |||
| Downside Variance | 1.89 | |||
| Semi Variance | 1.44 | |||
| Expected Short fall | (1.39) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Vertex Pharmaceuticals
The number of cover stories for Vertex Pharmaceuticals depends on current market conditions and Vertex Pharmaceuticals' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Vertex Pharmaceuticals is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Vertex Pharmaceuticals' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Vertex Pharmaceuticals Short Properties
Vertex Pharmaceuticals' future price predictability will typically decrease when Vertex Pharmaceuticals' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Vertex Pharmaceuticals often depends not only on the future outlook of the potential Vertex Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Vertex Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 257.9 M | |
| Cash And Short Term Investments | 6.1 B |
Additional Tools for Vertex Stock Analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.